Modelling the clinical and economic implications of galantamine in the treatment of mild-to-moderate Alzheimer's disease in Germany

Journal of Medical Economics

Volumn 13, Issue 4, 2010, Pages 641-654

  Guo, Shien ^a   Hernandez, Luis ^a   Wasiak, Radoslaw ^a   Gaudig, Maren ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b JANSSEN CILAG GMBH   (Germany)

Author keywords

Alzheimer's disease; cholinesterase inhibitors; cost effectiveness; economic evaluation; galantamine; germany

Indexed keywords

GALANTAMINE; GINKGO BILOBA EXTRACT;

AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR CHANGE; COGNITION; COST BENEFIT ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL ASSESSMENT; GERMANY; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; SURVIVAL TIME;

AGED, 80 AND OVER; ALZHEIMER DISEASE; CAREGIVERS; DISEASE PROGRESSION; FEMALE; GALANTAMINE; GERMANY; GINKGO BILOBA; HUMANS; LONG-TERM CARE; MALE; MODELS, ECONOMIC; NOOTROPIC AGENTS; SEVERITY OF ILLNESS INDEX;

EID: 78650057940     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696998.2010.528101     Document Type: Article

References (51)

1. Cummings JL. Alzheimer's disease. N Engl J Med 2004;351:56-67
2. Alzheimer's Disease International. World Alzheimer Report 2009, London 2009
3. Mahlberg R, Gutzmann H. Diagnostik von Demenzerkrankungen. Deutsches Ärzteblatt 2005;102:A2032-2039
4. Forsyth E, Ritzline PD. An overview of the etiology, diagnosis, and treatment of Alzheimer disease. Phys Ther 1998;78:1325-1331
5. BMG. Available at: Http://www.bmg.bund.de/cln-110/nn-1168278/Shared Docs/Standardartikel/DE/AZ/D/Glossarbegriff-Demenz.html. Accessed 5 December 2008
6. Wimo A, Winblad B, Jönsson L. The worldwide societal costs of dementia. Alzheimers Dement 2009;6:98-103
7. Jönsson L, Wimo A. The cost of dementia in Europe: A review of the evidence, and methodological considerations. Pharmacoeconomics 2009;27:391-403
8. Cummings JL. Treatment of Alzheimer's disease: current and future therapeutic approaches. Rev Neurol Dis 2004;1:60-69
9. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:2261-2268
10. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebocontrolled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54:2269-2276
11. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Cholinesterasehemmer bei Demenz, Abschlussbericht, Auftrag A05-19A, 07.02.2007, www.iqwig.de
12. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Aktualisierungsrecherche zum Bericht A09-19A (Cholinesterasehemmer bei Demenz). Rapid Report, Auftrag A09-03, 12.10.2009, www.iqwig.de
13. Sano M, Wilcock GK, van Baelen B, et al. The effects of galantamine treatment on caregiver time in Alzheimer's disease. Int J Geriatr Psychiatry 2003;18: 942-950
14. Feldman HH, Pirttila T, Dartigues JF, et al. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. Int J Geriatr Psychiatry 2009; 24:479-488
15. Caro JJ, Getsios D, Migliaccio-Walle K, et al. Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care. Neurology 2001;57:964-971
16. Ward A, Caro JJ, Getsios D, et al. Assessment of health economics in Alzheimer's disease (AHEAD): Treatment with galantamine in the UK. Int J Geriatr Psychiatry 2003;18:740-747
17. Migliaccio-Walle K, Getsios D, Caro JJ, et al. Economic evaluation of galantamine in the treatment of mild to moderate Alzheimer's disease in the United States. Clin Ther 2003;25:1806-1825
18. Caro JJ, Salas M, Ward A, et al. Assessment of Health Economics in Alzheimer's Disease. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands. Dement Geriatr Cogn Disord 2002; 14:84-89
19. Garfield FB, Getsios D, Caro JJ, et al. Assessment of Health Economics in Alzheimer's Disease (AHEAD): Treatment with galantamine in Sweden. Pharmacoeconomics 2002;20:629-637
20. Getsios D, Caro JJ, Caro G, et al. Assessment of health economics in Alzheimer's disease (AHEAD): Galantamine treatment in Canada. Neurology 2001;57:972-978
21. Gemeinsamer Bundesausschuss (G-BA). Arzneimittelrichtlinie - Anlage III: Übersicht über Versorgungseinschränkungen und -ausschlüsse in der Arzneimittelversorgung durch die Arzneimittelrichtlinie und aufgrund anderer Vorschriften (x 34 Abs. 1 Satz 6 und Abs. 3 SGB V), 19.02.2010
22. Gemeinsamer Bundesausschuss (G-BA). Ergänzungsauftrag zur Nutzenbewertung von Cholinesterasehemmern zur Behandlung der Alzheimer Demenz. 18.12.2009, http://www.g-ba.de/downloads/39-261- 1075/2009-12-17-IQWiG- Cholinesterasehemmern.pdf
23. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Allgemeine Methoden zur Bewertung von Verhältnissen zwischen Kosten und Nutzen. Version 1.0, 12.10.2009, www.iqwig.de
24. Caro JJ. Pharmacoeconomic analyses using discrete event simulation. Pharmacoeconomics 2005;23:323-332
25. Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. Br Med J 2000; 321:1445-1449
26. Caro J, Ward A, Ishak K, et al. To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers? BMC Neurol 2002;2:6
27. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). Ginkgohaltige Präparate bei Alzheimer Demenz. Auftrag A05-19B, Abschlussbericht. 29.09.2008, www.iqwig.de
28. National Institute for Health and Clinical Excellence (NICE). Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's disease. MidCity Mace, London, November 2006. Available at: www.nice. org.uk. Accessed 9 December 2008
29. Gesundheitsberichterstattung des Bundes. Available at: Http://www.gbebund. de/. Accessed 15 November 2009
30. Stern RG, Mohs RC, Davidson M, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994;151:390-396
31. Wilkinson D, Murray J. Galantamine: A randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2001; 16:852-857
32. Rockwood K, Mintzer J, Truyen L, et al. Effects of a flexible galantamine dose in Alzheimer's disease: A randomized, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589-595
33. Brodaty H, Corey-Bloom J, Potocnik FCV, et al. Comparison of the efficacy and tolerability of galantamine prolonged- and immediate-release formulations in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2005;20:120-132
34. Aronson SM, Baelen B van, Kershaw P. Greater benefits for patients receiving sustained vs. interrupted treatment with galantamine. The 9th International Conference on Alzheimer's Disease and Related Diseases, Philadelphia, USA, July 17-22, 2004
35. Schneider LS, DeKosky ST, Farlow MR, et al. A randomized, double-blind, placebo-controlled trial of two doses of ginkgo biloba extract in dementia of the Alzheimer's Type. Curr Alzheimer Res 2005;2:541-551
36. German Life Table 2006. Available at: Http://www.mortality.org/hmd/ DEUTNP/STATS/mltper-1x1.txt. Accessed 15 October 2009
37. Fitzpatrick AL, Kuller LH, Lopez OL, et al. Survival following dementia onset: Alzheimer's disease and vascular dementia. J Neurol Sci 2005;229:43-49
38. IMS Health, IMS Disease Analyzer, Jan 2008 - Dec 2008 JC data on file. IMS Health Deutschland. http://www.imshealth.de/sixcms/detail.php/307, letzter Zugriff 20.01.2010
39. Lauer-Taxe Online, www.lauer-fischer.de. Accessed 20 October 2009
40. Schwabe U, Paffrath (Hrsg.) D. Arzneiverordnungsreport 2008. Berlin, Heidelberg: Springer-Verlag, 2008:305-317
41. Kassenärztliche Bundesvereinigung.Einheitlicher Bewertungsmaß stab, Stand 01.01.2009, http://www.kbv.de/ebm2010/ebmgesamt.htm. Accessed 4 November 2009
42. Bundesministerium für Gesundheit. www.bmgs.de. Accessed 27 October 2009
43. Kulp W, Graf v.d. Schulenburg J-M. Pharmakoökonomische Aspekte der Behandlung von Demenz-Patienten. Pharmazie unserer Zeit 2002;31: 410-416
44. Gräßel E, Donath C, Lauterberg J, et al. Demenzkranke und Pflegestufen: Wirken sich Krankheitssymptome auf die Einstufung aus? Gesundheitswesen 2008;70:129-136
45. Feldman HH, Van Baelen B, Kavanagh SM, et al. Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: A 12-month analysis. Alzheimer Dis Assoc Disord 2005;19:29-36
46. Teipel SJ, Ewers M, Reisig V, et al. Long-term cost-effectiveness of donepezil for the treatment of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 2007;257:330-336
47. Tun SM, Murman DL, Long HL, et al. Predictive validity of neuropsychiatric subgroups on nursing home placement and survival in patients with Alzheimer disease. Am J Geriatr Psychiatry 2007;15:314-327
48. Getsios D, Blume S, Ishak KJ, et al. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: A UK evaluation using discrete-event simulation. Pharmacoeconomics 2010;28:411-427
49. Feldman HH, Pirttila T, Dartigues JF, et al. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. Int J Geriatr Psychiatry 2009; 24:479-488
50. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2009;CD003120
51. Weyerer S. Altersdemenz. Robert-Koch-Institut (RKI) (ed.) Gesundheitsberichtserstattung des Bundes - Heft 28. 15.11.2005, www.rki.de